These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33317342)

  • 21. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of flash glucose monitoring in pregnant women with poorly controlled pregestational diabetes (FlashMom): A randomized pilot study.
    Tumminia A; Milluzzo A; Festa C; Fresa R; Pintaudi B; Scavini M; Vitacolonna E; Napoli A; Sciacca L
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1851-1859. PubMed ID: 33975741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood glucose and free insulin levels after the administration of insulin by conventional syringe or jet injector in insulin treated type 2 diabetics.
    Kerum G; Profozić V; Granić M; Skrabalo Z
    Horm Metab Res; 1987 Sep; 19(9):422-5. PubMed ID: 3319860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK; Sibal L; Ashwell SG; Home PD
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus: A 16-week, multicenter, randomized clinical trial (the FREE study).
    Ji L; Gao L; Chen L; Wang Y; Ma Z; Ran X; Sun Z; Xu X; Wang G; Guo L; Shan Z
    EClinicalMedicine; 2020 Jun; 23():100368. PubMed ID: 32529176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
    Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
    Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
    Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
    Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A comparative study of the effects of needle free (INJEX30) versus insulin pen injection on insulin absorption in diabetic patients].
    Zhou MC; Wang Y; Dong YX; Sun Q; Li YX
    Zhonghua Nei Ke Za Zhi; 2013 Sep; 52(9):741-4. PubMed ID: 24314163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology.
    Engwerda EE; Abbink EJ; Tack CJ; de Galan BE
    Diabetes Care; 2011 Aug; 34(8):1804-8. PubMed ID: 21715522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Review of Randomized Controlled Trials Evaluating Glycemic Efficacy and Patient Satisfaction of Intermittent-Scanned Continuous Glucose Monitoring in Patients with Diabetes.
    Cowart K; Updike W; Bullers K
    Diabetes Technol Ther; 2020 May; 22(5):337-345. PubMed ID: 31859531
    [No Abstract]   [Full Text] [Related]  

  • 36. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction.
    Everett CC; Reynolds C; Fernandez C; Stocken DD; Sharples LD; Sathyapalan T; Heller S; Storey RF; Ajjan RA
    Diab Vasc Dis Res; 2020; 17(5):1479164120957934. PubMed ID: 33081502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
    Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
    Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study.
    Hakeam HA; Mulia HA; Azzam A; Amin T
    JPEN J Parenter Enteral Nutr; 2017 Sep; 41(7):1110-1118. PubMed ID: 27091835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.